SA
GILD icon

Strategic Advocates’s Gilead Sciences GILD Stock Holding History

Strategic Advocates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.46K Sell
32
-118
-79% -$16.5K 0.02% 189
2025
Q4 		$18.4K Buy
150
+44
+42% +$5.35K ﹤0.01% 299
2025
Q3 		$11.8K Buy
+106
New +$12K ﹤0.01% 340

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Strategic Advocates's GILD Position: Q1 2026 in Review

Strategic Advocates reduced its Gilead Sciences (GILD) stake by 79% in Q1 2026, selling an estimated $16.5K and leaving 32 shares worth $4.46K. The position accounts for 0.02% of the portfolio, ranked #189.

Strategic Advocates first reported a position in GILD in Q3 2025 and has held it in 3 quarters since. The position peaked at $18.4K in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Strategic Advocates held 32 shares of Gilead Sciences worth $4.46K as of Q1 2026.
  • Strategic Advocates sold 118 Gilead Sciences shares in Q1 2026, an estimated $16.5K.
  • Gilead Sciences made up 0.02% of Strategic Advocates's portfolio in Q1 2026, its #189 holding.
  • Strategic Advocates first reported a position in Gilead Sciences in Q3 2025 and has held it in 3 quarters since.
  • Strategic Advocates's Gilead Sciences position peaked at $18.4K in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.